These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18467248)

  • 1. Determination of the concentration of ciprofloxacin in prostate tissue following administration of a single, 1000 mg, extended-release dose.
    Lugg J; Lettieri J; Stass H; Agarwal V
    J Chemother; 2008 Apr; 20(2):213-8. PubMed ID: 18467248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a 3-day with a 1-day regimen of an extended-release formulation of ciprofloxacin as antimicrobial prophylaxis for patients undergoing transrectal needle biopsy of the prostate.
    Schaeffer AJ; Montorsi F; Scattoni V; Perroncel R; Song J; Haverstock DC; Pertel PE
    BJU Int; 2007 Jul; 100(1):51-7. PubMed ID: 17552953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
    Schuck EL; Dalhoff A; Stass H; Derendorf H
    Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic prophylaxis for transrectal prostate biopsy: a comparison of one-day and five-day regimen.
    Agbugui JO; Obarisiagbon EO; Osaigbovo EO; Osime CO; Akumabor PN
    Niger Postgrad Med J; 2014 Sep; 21(3):213-7. PubMed ID: 25331236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transrectal ultrasound guided prostate biopsy in the era of increasing fluoroquinolone resistance: prophylaxis with single-dose ertapenem.
    Seitz M; Stief C; Waidelich R; Bader M; Tilki D
    World J Urol; 2017 Nov; 35(11):1681-1688. PubMed ID: 28470334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ciprofloxacin concentration in human prostatic tissue following 3 days' administration].
    Morita M; Nakagawa H; Suzuki K
    Hinyokika Kiyo; 1991 May; 37(5):563-6. PubMed ID: 1713402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin.
    Lista F; Redondo C; Meilán E; García-Tello A; Ramón de Fata F; Angulo JC
    Actas Urol Esp; 2014; 38(6):391-6. PubMed ID: 24775812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis.
    Rhodes NJ; Gardiner BJ; Neely MN; Grayson ML; Ellis AG; Lawrentschuk N; Frauman AG; Maxwell KM; Zembower TR; Scheetz MH
    J Antimicrob Chemother; 2015 Jul; 70(7):2068-73. PubMed ID: 25802286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?
    Gardiner BJ; Mahony AA; Ellis AG; Lawrentschuk N; Bolton DM; Zeglinski PT; Frauman AG; Grayson ML
    Clin Infect Dis; 2014 Feb; 58(4):e101-5. PubMed ID: 24170195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in hospital admissions with the addition of prophylactic intramuscular ceftriaxone before transrectal ultrasonography-guided prostate biopsies.
    Luong B; Danforth T; Visnjevac O; Suraf M; Duff M; Chevli KK
    Urology; 2015 Mar; 85(3):511-6. PubMed ID: 25596154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Concentration of ciprofloxacin in bone tissue].
    Meissner A; Borner K
    Aktuelle Traumatol; 1993 Apr; 23(2):80-4. PubMed ID: 8098576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy.
    Cam K; Kayikci A; Akman Y; Erol A
    Int J Urol; 2008 Oct; 15(11):997-1001. PubMed ID: 18721198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy.
    Briffaux R; Coloby P; Bruyere F; Ouaki F; Pires C; Doré B; Irani J
    BJU Int; 2009 Apr; 103(8):1069-73; discussion 1073. PubMed ID: 19021604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose antibiotic prophylaxis in core prostate biopsy: Impact of timing and identification of risk factors.
    Lindstedt S; Lindström U; Ljunggren E; Wullt B; Grabe M
    Eur Urol; 2006 Oct; 50(4):832-7. PubMed ID: 16750292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg.
    Naber KG; Sörgel F; Kinzig M; Weigel DM
    J Urol; 1993 Nov; 150(5 Pt 2):1718-21. PubMed ID: 8411457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic modeling to establish the role of P-glycoprotein on ciprofloxacin distribution to lung and prostate following intravenous and intratracheal administration to Wistar rats.
    Zimmermann ES; de Miranda Silva C; Neris C; Torres BGDS; Schmidt S; Dalla Costa T
    Eur J Pharm Sci; 2019 Jan; 127():319-329. PubMed ID: 30423435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
    Torkildsen G; O'Brien TP
    Clin Ther; 2008 Nov; 30(11):2005-14. PubMed ID: 19108788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.